|
2019 |
2020 |
Create chart |
| Net sales revenues |
5,011,706 |
5,879,616 |
|
| Change in Fair Value of Biological Assets |
126,045 |
117,270 |
|
| Cost of Goods Sold |
-3,174,480 |
-3,586,746 |
|
| Depreciation / Amortization / exhaustion |
-498,430 |
-453,953 |
|
| Exhaustion of biological assets |
-170,697 |
-104,367 |
|
| Gross Profit |
1,294,144 |
1,851,820 |
|
| Selling Expenses |
-715,981 |
-781,150 |
|
| General and Administrative Expenses |
-215,162 |
-237,878 |
|
| Management Compensation |
-16,879 |
-17,987 |
|
| Other Operating Compensation |
293,319 |
-76,298 |
|
| Equity income from subsidiaries |
0 |
-66,624 |
|
| Operating Profit before Financial Income and Equity |
639,441 |
671,883 |
|
| Financial Income |
103,091 |
132,149 |
|
| Financial Expenses |
-263,521 |
-269,287 |
|
| Income Before Income Tax and Social Contribution |
479,011 |
534,745 |
|
| Income and social contribution taxes - current |
-159,612 |
-104,525 |
|
| Income Tax and Social Contribution - Deferred |
86,328 |
23,763 |
|
| Effect profit from discontinued operation |
null |
0 |
|
| Net Income |
405,727 |
453,983 |
|
| Recurring Net Income |
275,051 |
528,180 |
|
| Recurring EBITDA |
908,858 |
1,288,306 |
|
| EBITDA Margin |
18.7 % |
21.9 % |
|
* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex
**from 1Q 12 the data does not include discontinued operation, Deca Piazza
